Gan & Lee и Menarini Group сотрудничают для продвижения бофанглутида в Европе

Gan & Lee заключила эксклюзивное лицензионное соглашение с Menarini по бофанглутиду (GZR18) для рынков Европы и ещё 39 стран. Менарини обязуется подать регуляторные документы и вести коммерциализацию; Gan & Lee может получить аванс 62 млн евро, поэтапные платежи до 664 млн евро и двузначные роялти, а совокупная потенциальная стоимость сделки — до 726 млн евро без учёта роялти. Препарат с режимом дозирования 1 раз в 2 недели нацеливается на снижение частоты введения на 50% относительно недельных GLP-1 RA.

Analysis

The real asset here is not the upfront cash; it is the transfer of regulatory and commercialization optionality from a cash-constrained developer to a partner with European execution. That lowers Gan & Lee’s funding risk and makes the franchise more financeable, which can matter more for valuation than the headline consideration because it reduces the odds of equity dilution over the next 12-24 months.

For incumbents, the near-term threat to NVO and LLY is minimal; this is too early and too regional to change share, pricing, or demand forecasts. The second-order effect is on Europe’s obesity bidding war: a differentiated dosing schedule could support payer conversations if it reaches market, but the more immediate spillover is positive read-through for other non-US metabolic assets seeking ex-US licensing, especially Chinese innovators and specialty pharma distributors.

The catalyst path is long. Over the next 1-3 months, the market will mostly trade the partnership validation and the announced phase-3 intent; the real re-rating trigger is protocol initiation and whether regulators force additional safety or outcomes work, which would push monetization out 6-18 months. Contrarian view: the market may overpay for the licensing economics and underpay for development risk — a double-digit royalty on a pre-approval asset is nice, but it is still a very low-probability call option until European data and reimbursement terms are visible.

Key Decisions for Investors

• For accounts with access to A-shares, buy 603087.SH on pullbacks rather than chasing the first print; treat this as 6-12 month optionality on an ex-China obesity platform. Risk/reward is attractive only if the stock can hold the post-news gain and management confirms phase-3 start within the next two quarters.
• Do not short NVO or LLY on this headline; the timeline is too long and the asset is too unproven to justify share-loss assumptions. Revisit only if EU phase-3 data show materially better adherence or pricing power than weekly GLP-1s.
• Set a hard alert on 603087.SH if European phase-3 initiation slips by more than 1-2 quarters or if EMA/FDA feedback requires a much larger safety package; that would likely compress the deal-option premium and justify taking profits or cutting exposure.
• Small tactical long XBI only on confirmation that this kind of licensing is becoming a broader funding solution for obesity/metabolic biotech; otherwise stay flat. The trade works only as a sentiment basket, not as a single-asset fundamental call.